Trial Profile

International Open-Label Extension of the Phase 3 Study CL-503012 with KIACTA in Patients with AA Amyloidosis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eprodisate (Primary)
Indications Amyloid A amyloidosis
Focus Adverse reactions; Therapeutic Use
Sponsors Auven Therapeutics

Most Recent Events

28 Feb 2017 Status changed from recruiting to discontinued, according to a BELLUS Health media release. The company has decided to discontinue the development of Eprodisate for Amyloid-A-amyloidosis based on the results from a phase III study (Profile 700238113).
30 Jul 2016 This trial was discontinued in Poland (end date: 2016-06-20) according to European Clinical Trials Database record.
02 Jul 2016 The trial was prematurely ended in Lithuania (end date: 2016-06-20).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com